SCHEMBL18464545

SCHEMBL18464545

C=C(CC)c1ccc2cc(Br)ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 2/20 0.46
▸ ALDH1A1 P00352 3/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HDAC1 Q13547 3/20 0.36
▸ HDAC2 Q92769 3/20 0.36
▸ TLR2 O60603 1/20 0.36
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CYP2A6 P11509 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SLC6A2 P23975 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18463879 0.89 BACE1 (0.44) BACE1ALDH1A1SMN1; SMN2ABCG2CYP1A2
SCHEMBL263666 0.81 BACE1 (0.50) BACE1ALDH1A1SMN1; SMN2HDAC1HDAC2
SCHEMBL27887111 0.81 BACE1 (0.46) BACE1ALDH1A1SMN1; SMN2HDAC1HDAC2
SCHEMBL1294236 0.80 ALDH1A1 (0.48) BACE1ALDH1A1SMN1; SMN2HDAC1HDAC2
SCHEMBL18463872 0.78 ALDH1A1 (0.37) BACE1ALDH1A1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL7602003 0.75 BACE1 (0.47) BACE1ALDH1A1SMN1; SMN2HDAC1HDAC2
SCHEMBL262639 0.75 BACE1 (0.50) BACE1ALDH1A1SMN1; SMN2HDAC1HDAC2
SCHEMBL2001591 0.74 ALDH1A1 (0.65) BACE1ALDH1A1SMN1; SMN2ABCG2CYP1A2
SCHEMBL1000331 0.73 MGAM (0.56) BACE1ALDH1A1SMN1; SMN2HDAC1HDAC2
SCHEMBL1293647 0.72 BACE1 (0.47) BACE1ALDH1A1SMN1; SMN2HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170029372-A1 BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170029372-A1 BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE KLK3, SHBG, ACP3 BACE1 1738/4885ALDH1A1 2387/4885SMN1; SMN2 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback